Virogin Raises $62 Million for Oncolytic Virus Portfolio

Virogin Biotech, a Vancouver company developing oncolytic virus immunotherapies, raised $62 million in a Series C financing from China investors. Virogin has R&D facilities in Vancouver and Shanghai . Earlier this year, Virogin started a Phase I trial in Australia of its lead drug, VG161, an attenuated herpes simplex virus type 1 (HSV-1), that expresses cytokines to boost innate and adaptive immune responses inside the tumor. The C round was co-led by CMG-SDIC Capital and CDH Investments. More details.... Share this with colleagues: // //